- Home
- APLT vs AADI Comparison
APLT vs AADI Comparison
Compare APLT & AADI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- AADI
- Stock Information
- Founded
- APLT 2016
- AADI 2011
- Country
- APLT United States
- AADI United States
- Employees
- APLT N/A
- AADI N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- AADI Biotechnology: Pharmaceutical Preparations
- Sector
- APLT Health Care
- AADI Health Care
- Exchange
- APLT Nasdaq
- AADI Nasdaq
- Market Cap
- APLT 80.3M
- AADI 77.5M
- IPO Year
- APLT 2019
- AADI N/A
- Fundamental
- Price
- APLT $0.53
- AADI $2.79
- Analyst Decision
- APLT Buy
- AADI Hold
- Analyst Count
- APLT 7
- AADI 3
- Target Price
- APLT $6.10
- AADI $1.75
- AVG Volume (30 Days)
- APLT 3.0M
- AADI 114.1K
- Earning Date
- APLT 03-05-2025
- AADI 03-12-2025
- Dividend Yield
- APLT N/A
- AADI N/A
- EPS Growth
- APLT N/A
- AADI N/A
- EPS
- APLT N/A
- AADI N/A
- Revenue
- APLT N/A
- AADI $25,070,000.00
- Revenue This Year
- APLT N/A
- AADI $8.43
- Revenue Next Year
- APLT $2,622.90
- AADI $5.41
- P/E Ratio
- APLT N/A
- AADI N/A
- Revenue Growth
- APLT N/A
- AADI 7.80
- 52 Week Low
- APLT $0.53
- AADI $1.21
- 52 Week High
- APLT $10.62
- AADI $3.81
- Technical
- Relative Strength Index (RSI)
- APLT 29.75
- AADI 48.57
- Support Level
- APLT $0.54
- AADI $2.56
- Resistance Level
- APLT $0.70
- AADI $2.94
- Average True Range (ATR)
- APLT 0.06
- AADI 0.13
- MACD
- APLT 0.06
- AADI 0.01
- Stochastic Oscillator
- APLT 0.00
- AADI 57.50
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About AADI Aadi Bioscience Inc.
Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.